Amarin Corporation plc (the Company) has established a
website, https://www.voteamarin.com/, to communicate with the Companys shareholders regarding its solicitation of proxies from shareholders at the Companys 2023 Special General Meeting of Shareholders. Below are press
releases issued by the Company and other communication released on February 16, 2023, which are posted to such website. The Company has filed a definitive proxy statement (DEFC14A) and WHITE proxy card with the U.S. Securities and Exchange
Commission in connection with its solicitation of proxies from shareholders. Shareholders are strongly encouraged to read such proxy statement and accompanying WHITE proxy card as they contain important information.
The following is a press release issued by the Company:
Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards
Sarissa Issued its False Release Hours After Receiving Confirmation That All Proxy Cards Were Being Accepted
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ: AMRN) (Amarin or the
Company) today corrected the record regarding the latest misinformation from Sarissa Capital Management (Sarissa). Contrary to Sarissas press release, Amarin clearly and definitively instructed its registrar to accept
ALL submitted proxy cards, including both blue and white cards, with regard to its upcoming General Meeting of Shareholders. This is standard practice for a contested solicitation process and was established before the proxy solicitation process
even began. The idea that a company registrar would only accept one set of proxy cards is categorically false.
This is yet another example of
Sarissas focus on advancing its own interests at the expense of all Amarin shareholders. The registrar confirmed that it notified Sarissa eight hours in advance of their press release that all proxy cards were being considered. It is clear
that Sarissa is willing to say anything in an attempt to get on the Board.
In a note dated February 16, 2023, from the registrar:
As mentioned, [the registrar] did not advise [Sarissa] that Amarin were not accepting these proxy cards. As this was a different proxy
form that [the registrar] had seen before, we had to check with Amarin if we were to accept it. Amarin advised that we were able to accept therefore we have lodged the votes.
As this confirmation shows, the registrar was clearly instructed to accept all proxy cards, including Sarissas blue proxy card.
Materials regarding the Board of Directors recommendations for the General Meeting can be found at www.voteamarin.com.
About Amarin
Amarin is an innovative pharmaceutical
company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in
Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the
cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.